fasn in 1

FASN- in -1是一种有效的、特异性的脂肪酸合成酶(FASN)抑制剂，是一种专门设计用于靶向和抑制FASN 活性的化合物，是一种参与脂肪酸合成的酶，可抑制FASN 活性可以破坏脂肪酸的产生，并可能影响各种细胞过程。

FAS-IN-1 is a potent inhibitor of Fatty acid synthase (FAS) wtih IC50 of 10 nM.

UCM05 (G28UCM) (G28UCM) 是一种有效的脂肪酸合酶 (FASN) 抑制剂，对 HER2+ 乳腺癌异种移植物具有作用活性，且在抗 HER2 耐药细胞系中具有活性。UCM05 是一种丝状温度敏感蛋白 Z (FtsZ) 抑制剂，可抑制革兰氏阳性菌B. subtilis 生长，MIC 值为 100 μM，但对革兰氏阴性菌E. coli 缺乏活性。

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.

Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg kg) decreases serum cholesterol levels and total bod......

CTL-06是一种Fatty Acid Synthase (FASN)抑制剂，具有3 μM的IC50，能够诱发细胞凋亡。CTL-12导致细胞周期在Sub-G1 S期停滞，并增加caspase-9和凋亡标志物Bax的表达，减少抗凋亡标志物Bcl-xL的表达。此外，CTL-12通过抑制脂肪酸的从头合成，剥夺肿瘤细胞代谢所需，主要用于乳腺癌和结直肠癌的研究。

CTL-12是一种Fatty Acid Synthase (FASN)抑制剂（IC50: 2.5 μM），能够诱导apoptosis。它使细胞周期在Sub-G1 S期停滞并增加caspase-9和凋亡标志物Bax的表达，同时减少抗凋亡标志物Bcl-xL的水平。CTL-12通过抑制de novo脂肪酸合成，切断了肿瘤细胞的代谢需求，是乳腺癌和结直肠癌研究中的重要工具。

FASN-IN-6（Compound 44）作为脂肪酸生物合成（FAB）抑制剂表现出高效性。该化合物具备抗菌作用，针对金黄色葡萄球菌ATCC 25923及粪肠球菌ATCC 29212的最小抑菌浓度（MIC）分别为1 μg mL与4 μg mL。